文献速递血栓与止血

基于2018-2022年美国食品药品监督管理局不良事件报告系统数据比较因子VIII产品与艾美赛珠单抗治疗患者的血栓不良事件

Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data.
PubMed 文献 · J Thromb Haemost · 2024-02-22

该药物安全性研究利用美国食品药品监督管理局不良事件报告系统2018-2022年数据,对艾美赛珠单抗与因子VIII产品的血栓不良事件进行不成比例分析。艾美赛珠单抗的血栓不良事件报告比例高于因子VIII产品,比值比约3倍,排除旁路制剂共同报告后仍较高。

要点

  • 艾美赛珠单抗血栓不良事件报告比例4.07%,因子VIII产品1.44%。
  • 艾美赛珠单抗报告比值比2.91,约3倍于因子VIII产品。
  • 排除旁路制剂共同报告后,艾美赛珠单抗报告比例仍较高,PRR=2.19。

核心结论

  • 在美国食品药品监督管理局不良事件报告系统数据中,艾美赛珠单抗的血栓不良事件报告频率约为因子VIII产品的3倍。
  • 未来需要更多研究和努力来监测、阐明和预防血友病治疗(包括艾美赛珠单抗)中潜在的血栓不良事件风险。

研究设计与样本

  • 药物安全性研究,使用美国食品药品监督管理局不良事件报告系统2018-2022年数据。
  • 对艾美赛珠单抗与因子VIII产品的血栓不良事件进行不成比例分析,采用比例报告比、报告比值比和信息成分三种信号检测指标。

主要发现

  • 2018-2022年,艾美赛珠单抗的血栓不良事件占所有不良事件的比例为4.07%(97/2383),因子VIII产品为1.44%(134/9324)。
  • 艾美赛珠单抗 vs 因子VIII产品的PRR=2.83(2.19-3.66),ROR=2.91(2.23-3.79),IC=1.04(0.70-1.28)。
  • 旁路制剂作为共同报告药物在艾美赛珠单抗和因子VIII产品相关的总血栓不良事件报告中分别占36%和15%。
  • 排除含旁路制剂的报告后,艾美赛珠单抗 vs 因子VIII产品的血栓不良事件报告比例仍较高,PRR=2.19(1.60-2.99)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Relatively little is known about thrombotic adverse events (AEs) of emicizumab in postmarketing real-world settings, particularly in comparison with factor VIII (FVIII) products. A recent European study reported a potentially greater thrombotic risk of emicizumab compared with FVIII products. OBJECTIVES: This drug safety study aims to investigate whether thrombotic AEs are more frequently reported for emicizumab than for FVIII products and if so, whether it is independent of bypassing agents as coreporting drugs using the United States Food and Drug Administration Adverse Event Reporting System data. METHODS: Disproportionality analyses for thrombotic AEs of emicizumab vs FVIII products were conducted. Three signal detection indicators were used: proportional reporting ratio (PRR), reporting odds ratio (ROR), and informational component (IC). RESULTS: During 2018-2022, the proportions of thrombotic AEs among all AEs were 4.07% (97 out of 2383) and 1.44% (134 out of 9324) for emicizumab and FVIII products, respectively: PRR = 2.83 (2.19-3.66), ROR = 2.91 (2.23-3.79), and IC = 1.04 (0.70-1.28). Bypassing agents as coreporting drugs were identified in 36% and 15% of the total thrombotic AE reports associated with emicizumab and FVIII products, respectively. Even after thrombotic AE reports with bypassing agents were excluded, the reporting proportion of thrombotic AEs was still greater for emicizumab than for FVIII products: PRR = 2.19 (1.60-2.99). CONCLUSION: Thrombotic AEs in the United States Food and Drug Administration Adverse Event Reporting System data were about 3 times more frequently reported for emicizumab than for FVIII products. More research and efforts in the future are warranted for monitoring, elucidating, and preventing the potential risk of thrombotic AEs in hemophilia therapy, including emicizumab.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Cho H, Yoo KY, Shin JY, et al. Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data. J Thromb Haemost. 2024. PMID: 38395359. doi:10.1016/j.jtha.2024.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。